Osimertinib Mesylate
Osimertinib mesylate is a third-generation EGFR TKI for lung cancer with T790M mutation. The indoline-quinazoline structure qualifies as aromatic modified heterocyclic drug under HTS 2933.99.75.00.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If specific indole derivative
Indole provision in 2933.52 takes precedence over general drug category.
If as pharmaceutical preparation
Any further processing into preparations moves to Chapter 30.
If cyclic alcohol classification
If hydroxyl group considered principal function, classifies under alcohols.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Include polymorphic form designation (Form A) in import documentation
• Particle size distribution critical for bioavailability - include laser diffraction data
• Declare therapeutic class on entry summary to facilitate FDA review
Related Products under HTS 2933.99.75.00
Imatinib Mesylate
Imatinib mesylate is a tyrosine kinase inhibitor used primarily as an anticancer drug for treating chronic myeloid leukemia. This aromatic heterocyclic compound with nitrogen hetero-atoms falls under HTS 2933.99.75.00 as it is classified as a drug containing a modified aromatic nitrogen heterocyclic structure.
Erlotinib Hydrochloride
Erlotinib hydrochloride is an epidermal growth factor receptor (EGFR) inhibitor used in non-small cell lung cancer treatment. As a quinazoline derivative (aromatic heterocycle with nitrogen), it qualifies under HTS 2933.99.75.00 for aromatic heterocyclic drugs.
Nilotinib Hydrochloride
Nilotinib hydrochloride treats imatinib-resistant chronic myelogenous leukemia. As a pyrimidine derivative with aromatic nitrogen heterocycles, it falls under the 'drugs: other' provision of HTS 2933.99.75.00.
Gefitinib
Gefitinib is an EGFR tyrosine kinase inhibitor for lung cancer treatment. This 4-anilinoquinazoline (aromatic N-heterocycle) is classified as a bulk pharmaceutical drug under HTS 2933.99.75.00.
Brigatinib
Brigatinib is an ALK inhibitor for lung cancer treatment. This macrocyclic aromatic nitrogen-heterocycle drug substance imports under HTS 2933.99.75.00.
Alectinib Hydrochloride
Alectinib hydrochloride targets ALK fusion proteins in lung cancer. As an isoquinoline derivative (aromatic N-heterocycle), classified under HTS 2933.99.75.00 for drugs.